Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?

This article was originally published in The Pink Sheet Daily

Executive Summary

Much to the chagrin of industry, Health Minister Roxon has announced that the Cabinet will now make all decisions about what drugs are listed on the federal drug plan, regardless of price.
Advertisement

Related Content

Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
Australia Has Cheapest Drugs Compared To OECD Countries, UK Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS072331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel